48-week changes in biomarkers in subjects with high cardiovascular risk switching from ritonavir-boosted protease inhibitors to dolutegravir: the NEAT022 study

E. Martinez, L. Assoumou, G. Moyle, L. Waters, M. Johnson, P. Domingo, J. Fox, H. Stellbrink, G. Guaraldi, M. Masia, M. Gompels, S. de Wit, E. Florence, S. Esser, F. Raffi, A. Pozniak, J. Gatell

Research output: Contribution to journalConference abstract in journal

Original languageEnglish
JournalJournal of the International AIDS Society
Number of pages2
Publication statusPublished - 2018



Cite this